albumin-bound paclitaxel

P1/2, N=122, Recruiting, Oncolytics Biotech

P2, N=180, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting

P3, N=632, Completed, Fondazione Michelangelo | Active, not recruiting --> Completed

P3, N=501, Active, not recruiting, Revolution Medicines, Inc. | Recruiting --> Active, not recruiting

Despite initial responses to first-line firmonertinib-based combination therapy, progression-free survival (PFS) 13 months, the patient developed sequential resistance to subsequent regimens, including liver/brain metastases and treatment-related toxicities. After fourth-line therapy failure and severe intolerance to albumin-bound paclitaxel and bevacizumab, two cycles of ivonescimab-a first-in-class programmed cell death protein receptor-1 (PD-1)/vascular endothelial growth factor-A (VEGF-A) bispecific antibody-induced significant regression of pulmonary target lesions (PR), sustained over six cycles with minimal toxicity...While the rapid PR and favorable safety profile are promising, longer follow-up is required to assess durability and survival benefits. These findings underscore the need for further investigation of bispecific antibodies in precision oncology paradigms for multi-refractory EGFR-driven NSCLC.

P2, N=156, Not yet recruiting, The First Affiliated Hospital with Nanjing Medical University

P1/2, N=183, Recruiting, Tango Therapeutics, Inc. | N=133 --> 183

P2, N=60, Completed, Guangxi Medical University | Unknown status --> Completed | Trial completion date: Jun 2022 --> Oct 2025

P=N/A, N=96, Completed, Changhai Hospital | Recruiting --> Completed | Phase classification: P2 --> PN/A | Trial completion date: Dec 2024 --> Aug 2025 | Trial primary completion date: Dec 2023 --> Aug 2025

Second-line treatment with tislelizumab, nab-paclitaxel, carboplatin, and anlotinib led to temporary stabilization. Salvage chemotherapy with doxorubicin, ifosfamide, and dacarbazine failed, and the patient died two months later...Patients who undergo complete resection of metastatic lesions tend to achieve better outcomes, whereas responses to systemic therapy are generally poor. Early identification of high-risk features and consideration of retroperitoneal lymph node dissection may improve prognosis in selected patients.

According to the differences in NAC regimens, they were categorized into TCb group (n=50), docetaxel + doxorubicin + cyclophosphamide (TAC group, n=60), and epirubicin combined with cyclophosphamide followed by docetaxel (EC-T group, n=40). TNBC patients with high levels of NPAR, severe neutropenia, high Ki-67 expression, and lymph node stage I are more likely to achieve pCR. In addition, NPAR, Ki-67 expression and severe neutropenia were all good predictors of pCR, the better performance in predicting pCR after combining multiple metrics.

P2, N=104, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology